Lymphocytosis Interpreter
Lymphocytosis Interpreter
Two numbers decide most of this and they are constantly confused with each other. One is the lymphocyte count that makes a result lymphocytosis at all. The other is the clonal B-cell count of 5 × 10⁹/L that separates monoclonal B-cell lymphocytosis from chronic lymphocytic leukaemia — and it counts the clone, not the lymphocytes. This page keeps them apart, and is clear that monoclonal B-cell lymphocytosis is a diagnosis with a real annual rate of progression, not a way of saying nothing is wrong.
Is this lymphocytosis reactive or clonal?
Count + film + flow → reactive or clonalA 71-year-old has a lymphocyte count of 7.2 × 10⁹/L found on a routine blood count taken before a hernia repair. The film shows a monotonous population of small mature lymphocytes with numerous smudge cells. The count was also raised on a sample from four months ago. There is no lymphadenopathy or splenomegaly, the haemoglobin and platelet count are normal, and flow cytometry has not yet been done.
The two thresholds, and why they are not the same number
Chronic lymphocytic leukaemia requires at least 5 × 10⁹/L clonal B lymphocytes, sustained for three months, with clonality shown by flow cytometry. That is a count of the clone.
The two come apart whenever a reactive population sits alongside a clone. A lymphocyte count of 9 × 10⁹/L containing a 2 × 10⁹/L clone is not chronic lymphocytic leukaemia — it is monoclonal B-cell lymphocytosis with a reactive lymphocytosis on top, and the 9 is the number that misleads.
Worked example
A 71-year-old has a lymphocyte count of 7.2 × 10⁹/L found on a routine blood count taken before a hernia repair. The film shows a monotonous population of small mature lymphocytes with numerous smudge cells. The count was also raised on a sample from four months ago. There is no lymphadenopathy or splenomegaly, the haemoglobin and platelet count are normal, and flow cytometry has not yet been done.
No blasts, villous or hairy cells, so this is an excess of morphologically normal lymphocytes rather than an abnormal population
Flow cytometry has not been done, so no clonal B-cell count exists yet — and without it neither the CLL threshold nor the MBL threshold can be applied at all
Adult, and 7.2 is above both the 4.0 and the 4.5 definitions of lymphocytosis
7.2 is below 30, so the count alone is not the trigger for immunophenotyping
Monomorphic film with smudge cells → this is the trigger. Send flow cytometry and ask for the clonal B-cell count as a number
Note what the 7.2 does not tell you. It is above 5, but 5 × 10⁹/L is a threshold for the clone, not for the lymphocytes. If the clone turns out to be 3.1 × 10⁹/L this is high-count monoclonal B-cell lymphocytosis, not chronic lymphocytic leukaemia — and the four-month history means the duration criterion would already be satisfied either way
The three B-cell outcomes, once the clone has been counted
| Clonal B-cell count (× 10⁹/L) | Diagnosis | What happens next |
|---|---|---|
| Under 0.5 | Low-count monoclonal B-cell lymphocytosis | Common with age; progression to CLL needing treatment is very rarely observed. Usually no haematology follow-up for the clone itself |
| 0.5 to under 5 | High-count monoclonal B-cell lymphocytosis | Progresses to CLL requiring treatment at about 1 to 2 per cent per year. Annual review; assess any new node, cytopenia or symptom promptly |
| 5 or more | Chronic lymphocytic leukaemia (count criterion met) | Confirm it is sustained over three months and that the immunophenotype is not mantle cell. Stage; most early disease is observed |
Reactive against clonal, before flow cytometry is back
| Feature | Reactive | Clonal |
|---|---|---|
| Cell-to-cell appearance | Pleomorphic — varies from cell to cell | Monomorphic — the same cell repeated |
| Cytoplasm | Abundant, basophilic, moulds around red cells | Scanty |
| Smudge cells | Not a feature | Characteristic of CLL |
| Course | Follows an illness; settles within weeks | Persists; may climb slowly |
| Other lineages | Usually untouched | A cytopenia may accompany it |
| The test that decides | — | Flow cytometric immunophenotyping of the blood |
Monoclonal B-cell lymphocytosis is a finding, not a reassurance
The diagnostic criteria for chronic lymphocytic leukaemia are unusually explicit. At least 5 × 10⁹/L clonal B lymphocytes in the peripheral blood, sustained for at least three months, with clonality established by flow cytometry showing a CD5-positive, CD19-positive, CD23-positive population with light chain restriction and dim surface immunoglobulin. Everything in that sentence does work. The threshold is on the clone rather than on the lymphocyte count, so a patient with a large reactive lymphocytosis and a small clone does not have chronic lymphocytic leukaemia no matter how high the differential runs. The duration requirement excludes transient expansions. And the immunophenotype is what separates this from mantle cell lymphoma, which shares CD5 and which is treated altogether differently.
Below that threshold, with no lymphadenopathy, no organomegaly, no disease-related cytopenia and no symptoms, the finding is monoclonal B-cell lymphocytosis. It is tempting to present this to a patient as a normal variant, and that is not what the evidence supports. High-count monoclonal B-cell lymphocytosis — a clone of roughly 0.5 × 10⁹/L or more — progresses to chronic lymphocytic leukaemia requiring treatment at about 1 to 2 per cent per year. That is a low annual rate, and over a decade it is not a small cumulative one. It also carries an increased risk of infection and of second cancers that does not depend on progression. The honest framing is a condition that is being watched.
Low-count monoclonal B-cell lymphocytosis is genuinely different. Detected only when sensitive flow cytometry is used to look for it, present in a substantial minority of healthy older people, it very rarely progresses to disease requiring treatment. The distinction between the two is therefore not a matter of degree but of what should be said and done afterwards, and it depends on a number — the clone size — that only appears on the report if somebody asked for it.
Which brings the page back to its central point. The lymphocyte count is what prompts the question and the clonal B-cell count is what answers it, and they are different measurements of different things. A reader who applies the 5 × 10⁹/L threshold to the total lymphocyte count will diagnose chronic lymphocytic leukaemia in people who have a reactive lymphocytosis, and will reassure people whose clone is above the threshold while their total count happens to be modest. Ask the laboratory for the clonal B-cell count as a figure, and read the threshold against that.
Frequently asked questions
My patient’s lymphocyte count is 6.5 × 10⁹/L. Is that chronic lymphocytic leukaemia?
Not on that number. The 5 × 10⁹/L threshold applies to the clonal B-cell count measured by flow cytometry, not to the total lymphocyte count, and the two are different figures whenever a reactive population sits alongside a clone — or when there is no clone at all. A lymphocyte count of 6.5 might represent a clone of 6.0, a clone of 1.2, or nothing clonal whatsoever. Send flow cytometry and ask for the clonal B-cell count as a number.
What exactly is the difference between monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia?
The clone size and the absence of disease features. MBL is a clonal B-cell population below 5 × 10⁹/L with no lymphadenopathy, no organomegaly, no disease-related cytopenia and no symptoms. CLL is at least 5 × 10⁹/L clonal B lymphocytes sustained for three months — or a smaller clone accompanied by a cytopenia caused by marrow infiltration. If there is lymphadenopathy with a clone below the threshold and no cytopenia, the diagnosis is small lymphocytic lymphoma rather than either.
Is monoclonal B-cell lymphocytosis something to reassure the patient about?
It is something to explain accurately. High-count MBL progresses to CLL requiring treatment at roughly 1 to 2 per cent per year, which is low but real and which accumulates rather than falling away. It also carries an increased risk of infection and of second cancers independent of progression. Low-count MBL, with a clone below about 0.5 × 10⁹/L, behaves differently and very rarely progresses. The two should not be described in the same terms.
When should I send flow cytometry rather than repeat the count?
When there are lymphoblasts or any other abnormal lymphoid morphology; when the lymphocyte count is above about 30 × 10⁹/L; when an unexplained lymphocytosis has persisted beyond a month, and certainly beyond three; when there is an accompanying anaemia or thrombocytopenia; or when there is lymphadenopathy or hepatosplenomegaly and reactive causes have been excluded. A monomorphic film with smudge cells qualifies on its own.
Does a clonal T-cell population mean a T-cell malignancy?
No. Clonal and oligoclonal T-cell receptor rearrangements are found in viral infection, in autoimmune disease and simply with increasing age, so clonality alone is not evidence of malignancy in the T-cell lineage the way it broadly is in the B-cell lineage. T-cell large granular lymphocytic leukaemia — the commonest finding here — is diagnosed from a persistent large granular lymphocyte population with a compatible immunophenotype in a compatible clinical setting, often presenting with neutropenia rather than with the lymphocytosis, and it frequently needs no chemotherapy at all.
Related calculators
References
- Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
- Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679-1705.
- Bhatt VR, Saleem A. Lymphocytosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing.
- Riley LK, Rupert J. Evaluation of patients with leukocytosis. Am Fam Physician. 2015;92(11):1004-1011.
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-1719.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.